archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recent news: Diabetes Care Publishes Data Demonstrating PaQ® Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Study showed ease of use efficacy and high satisfaction among participants who transitioned from multiple daily insulin injections to PaQ device HORW Switzerland March 5 2014 PRNewswire CeQur SA a company focused on the development and commercialization of simple insulin delivery devices announced that comprehensive results from a clinical study of the company s PaQ Insulin Delivery Device were published online today in Diabetes Care a peer reviewed journal produced by the American Diabetes Association The paper titled A Feasibility Study of a Three Day Basal Bolus Insulin Delivery Device in Individuals with Type 2 Diabetes summarizes results from a study that evaluated the feasibility of transitioning people with type 2 diabetes from multiple

    Original URL path: http://www.endeavourvision.com/news-n216-c0-s22-Diabetes+Care+Publishes+Data+Demonstrati.htm (2016-04-25)
    Open archived version from archive


  • Recent news: CeQur to Present at the 32nd Annual J.P. Morgan Healthcare Conference
    2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs HORW Switzerland Jan 8 2014 PRNewswire CeQur SA a leader in simple insulin infusion for people with type 2 diabetes today announced that the company has been invited to present at the 32nd Annual J P Morgan Healthcare Conference in San Francisco CeQur management is scheduled to present an overview of the company at the Westin St Francis Hotel on Wednesday 15 January 2014 at 7 30 a m PT The Need for Simple Insulin Infusion There are currently more than 11 million people with type 2 diabetes T2D in the United States and the European Union who are taking daily insulin injections The majority of these people are not achieving target glycemic control Studies suggest that continuous subcutaneous insulin infusion

    Original URL path: http://www.endeavourvision.com/news-n211-c0-s22-CeQur+to+Present+at+the+32nd+Annual+J.P..htm (2016-04-25)
    Open archived version from archive

  • Recent news: Roche and Molecular Partners enter into alliance to develop new cancer treatments
    names Molecular Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Partnership will combine novel biologics DARPins with Roche drug conjugate technology Basel Switzerland Zurich Schlieren Switzerland 04 December 2013 Roche SIX RO ROG OTCQX RHHBY and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover develop and commercialize several proprietary therapeutics incorporating Molecular Partners DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer DARPin drug conjugates would be an exciting new class of drugs offering the potential of enhanced efficacy with substantial patient benefit over existing therapies DARPins are non antibody based small proteins where a variable region has been engineered for target binding Their

    Original URL path: http://www.endeavourvision.com/news-n210-c0-s22-Roche+and+Molecular+Partners+enter+into+.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Symetis Announces a Symbolic Milestone - the 1000th Patient Implanted with ACURATE TA™
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs ECUBLENS SWITZERLAND Oct 28 2013 Symetis Inc a privately owned Swiss company focused on transcatheter aortic valve implantation TAVI systems announced today that it has achieved a symbolic milestone the implantation of the 1000th ACURATE TA transaortic valve The first ACURATE TA valve was implanted in November 2009 at the Leipzig Herzzentrum by Pr T Walther and Dr J Kempfert ACURATE TA was granted CE mark in September 2011 and the first commercial implant was performed in November 2011 In April 2012 Symetis reported the clinical outcome of its SAVI Registry n 250 showing superior results in the patient population treated in everyday clinical settings more than 97 of patients with no relevant paravalvular leak PVL

    Original URL path: http://www.endeavourvision.com/news-n205-c0-s22-Symetis+Announces+a+Symbolic+Milestone+-.htm (2016-04-25)
    Open archived version from archive

  • Recent news: French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs MOUNTAIN VIEW Calif Oct 28 2013 PRNewswire PneumRx Inc www pneumrx com a leader in the field of interventional pulmonology today announced that enrollment in the REVOLENS Study a cost effectiveness study of the PneumRx RePneu Lung Volume Reduction Coil RePneu LVRC in France has been completed The REVOLENS study was submitted last year to the French Ministry of Health by Professors Gaetan Deslee of the University Hospital of Reims and Charles Hugo Marquette of the University Hospital of Nice and was accepted and funded by the Ministry of Health under the soutien aux techniques innovantes couteuses STIC program The STIC program provides government funding for innovative medical technologies that have been validated by prior clinical

    Original URL path: http://www.endeavourvision.com/news-n206-c0-s22-French+Cost-Effectiveness+Trial+of+Pneum.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI
    Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Symetis ACURATE TAVI TM to incorporate Endoluminal Sciences active anti paravalvular leak technology Complements Symetis ZeroLeak TM initiative ECUBLENS SWITZERLAND Sep 26 2013 Symetis Inc a privately owned Swiss company focusing on transcatheter aortic valve implantation TAVI systems announces today that it has entered into a license agreement with Endoluminal Sciences Sydney Australia to gain rights to their active anti paravalvular leak technology for the TAVI field Endoluminal Sciences has developed a unique solution to actively reduce paravalvular leak PVL based upon the company s proprietary swelling polymer and membrane technology Symetis will incorporate this technology into both the ACURATE TA TM and ACURATE TF TM product lines with the goal

    Original URL path: http://www.endeavourvision.com/news-n203-c0-s22-Symetis+and+Endoluminal+Sciences+enter+i.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting
    Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Data suggest PaQ may help people with type 2 diabetes maintain better glycemic control HORW Switzerland Sept 24 2013 CeQur SA a company focused on the development and commercialization of simple insulin delivery devices announced that comprehensive data from a study of the company s PaQ Insulin Delivery Device were presented today at the 49th Annual Meeting of the European Association for the Study of Diabetes EASD in Barcelona The data suggest that the discreet wearable PaQ device can potentially improve glycemic control among people with type 2 diabetes and is associated with both high patient acceptance and satisfaction Previous research suggests that approximately 50 percent of insulin requiring individuals do

    Original URL path: http://www.endeavourvision.com/news-n201-c0-s22-Data+Demonstrating+Potential+Benefits+of.htm (2016-04-25)
    Open archived version from archive

  • Recent news: BIND Therapeutics Announces Pricing of Initial Public Offering
    of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs CAMBRIDGE Mass EON Enhanced Online News BIND Therapeutics Inc a clinical stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins announced today the pricing of its initial public offering of 4 700 000 shares of its common stock at a public offering price of 15 00 per share before underwriting discounts and commissions The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol BIND on September 20 2013 In addition BIND has granted the underwriters a 30 day option to purchase up to an additional 705 000 shares of common stock at the same price to cover over allotments if any The offering is expected to close on September 25 2013

    Original URL path: http://www.endeavourvision.com/news-n200-c0-s22-BIND+Therapeutics+Announces+Pricing+of+I.htm (2016-04-25)
    Open archived version from archive



  •